Skip to main content
Search
News, Views, and Advocacy From the Oncology Nursing Society
ONS Voice Home
  • News & Views
  • Advocacy
  • Stories
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • News & Views
    • Latest Articles
    • Clinical Practice
    • ONS News
    • ONS Leadership
    Trending Topics
    • Treatments
    • Research
    • Safety
    • COVID-19
    • ONS Congress
    • Clinical practice
    View All Topics
    Advocacy
    • Latest Articles
    • Updates
    • Get Involved
    Stories View All
    View All
    Zoom Through Video Job Interviews With These Tips for Applicants and Hiring Managers
    nursing professional development
    Zoom Through Video Job Interviews With These Tips for Applicants and Hiring Managers
    January 22, 2021
    The Case of Concurrent Therapy Concerns
    Treatment side effects
    The Case of Concurrent Therapy Concerns
    December 18, 2020
    In a World Where You Can Be Anything, Be Kind
    Nurse staffing
    In a World Where You Can Be Anything, Be Kind
    December 11, 2020
    Nursing Innovation Links Rural Facilities to Resources and Experts to Provide High-Quality Care Across the Country
    Access to cancer care
    Nursing Innovation Links Rural Facilities to Resources and Experts to Provide High-Quality Care Across the Country
    December 04, 2020
    Why All Oncology Nurses Should Be Environmentalists
    Oncology nurse influence
    Why All Oncology Nurses Should Be Environmentalists
    November 27, 2020
    previous slide
    next slide
    Search
  • News & Views
  • Advocacy
  • Stories
  • Topic

    U.S. Food and Drug Administration (FDA)

    FDA Approves Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma
    Cancer treatments

    FDA Approves Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma

    On January 22, 2021, the U.S. Food and Drug Administration (FDA) approved nivolumab (Opdivo®) in combination with cabozantinib (Cabometyx®) as first-line treatment for patients with advanced renal cell carcinoma.

    January 25, 2021
    FDA Approves Fam-Trastuzumab Deruxtecan-Dxki for HER2-Positive Gastric Adenocarcinomas
    Cancer treatments

    FDA Approves Fam-Trastuzumab Deruxtecan-Dxki for HER2-Positive Gastric Adenocarcinomas

    On January 15, 2021, the U.S. Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (Enhertu®) for adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.

    January 19, 2021
    FDA Approves Crizotinib for Children and Young Adults With Relapsed or Refractory, Systemic ALK-Positive Anaplastic Large Cell Lymphoma
    Cancer treatments

    FDA Approves Crizotinib for Children and Young Adults With Relapsed or Refractory, Systemic ALK-Positive Anaplastic Large Cell Lymphoma

    On January 14, 2021, the U.S. Food and Drug Administration (FDA) approved crizotinib (Xalkori®) for pediatric patients aged one year or older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is anaplastic lymphoma kinase (ALK) positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refractory, systemic ALK-positive ALCL. 

    January 15, 2021
    Sunstar Americas, Inc., Expands Voluntary Nationwide Recall of Paroex® Chlorhexidine Gluconate Oral Rinse USP, 0.12%, for Microbial Contamination
    U.S. Food and Drug Administration (FDA)

    Sunstar Americas, Inc., Expands Voluntary Nationwide Recall of Paroex® Chlorhexidine Gluconate Oral Rinse USP, 0.12%, for Microbial Contamination

    On December 28, 2020, the U.S. Food and Drug Administration announced that Sunstar Americas, Inc., expanded its October 27, 2020, voluntary recall of Paroex® chlorhexidine gluconate oral Rinse USP, 0.12%, because of possible contaminated with the bacteria Burkholderia lata.

    January 06, 2021
    FDA Approves Selinexor for Relapsed or Refectory Multiple Myeloma
    U.S. Food and Drug Administration (FDA)

    FDA Approves Selinexor for Relapsed or Refectory Multiple Myeloma

    On December 18, 2020, the U.S. Food and Drug Administration (FDA) approved selinexor (Xpovio®) in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refectory multiple myeloma who have received at least one prior therapy. 

    December 21, 2020
    FDA Approves Osimertinib as Adjuvant Therapy for NSCLC With EGFR Mutations
    U.S. Food and Drug Administration (FDA)

    FDA Approves Osimertinib as Adjuvant Therapy for NSCLC With EGFR Mutations

    On December 18, 2020, the U.S. Food and Drug Administration (FDA) approved osimertinib (Tagrisso®) as adjuvant therapy after tumor resection for patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations, as detected by an FDA-approved test. 

    December 21, 2020
    FDA Approves Relugolix for Advanced Prostate Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Relugolix for Advanced Prostate Cancer

    On December 18, 2020, the U.S. Food and Drug Administration (FDA) approved the first oral gonadotropin-releasing hormone receptor antagonist, relugolix, (Orgovyx™) for adult patients with advanced prostate cancer. 

    December 21, 2020
    FDA Approves Margetuximab-cmkb for Metastatic HER2-Positive Breast Cancer
    Cancer treatments

    FDA Approves Margetuximab-cmkb for Metastatic HER2-Positive Breast Cancer

    On December 16, 2020, the U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb (Margenza™) in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who previously received two or more anti-HER2 regimens, at least one of which was for metastatic disease.

    December 18, 2020
    COVID-19 Reference Sheet: Vaccines
    COVID-19

    COVID-19 Reference Sheet: Vaccines

    To control the COVID-19 coronavirus pandemic, we need public health measures (e.g., masks, physical distancing, hand washing), treatments for infection, and vaccines to prevent infection or serious disease. In 2020, several manufacturers developed COVID-19 vaccines in less than a year. Before that, the fastest a vaccine had been developed was in four years.  

    December 14, 2020
    FDA Issues Emergency Use Authorization for First COVID-19 Vaccine
    U.S. Food and Drug Administration (FDA)

    FDA Issues Emergency Use Authorization for First COVID-19 Vaccine

    On December 11, 2020, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization for a vaccine to prevent the COVID-19 coronavirus caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 16 years of age and older. The emergency use authorization allows the Pfizer-BioNTech COVID-19 vaccine to be distributed in the United States. 

    December 14, 2020
    FDA Warns Against Wearing Face Masks With Metal During MRI Exams
    U.S. Food and Drug Administration (FDA)

    FDA Warns Against Wearing Face Masks With Metal During MRI Exams

    The U.S. Food and Drug Administration (FDA) issued an alert on December 7, 2020, informing patients and healthcare providers that patients may be injured if they wear face masks with metal parts and coatings during magnetic resonance imaging (MRI) exams. Metal parts (e.g., nose pieces, nanoparticles, or antimicrobial coatings that may contain metal such as silver or copper) may become hot and burn patients during MRIs. 

    December 10, 2020
    FDA Approves Pralsetinib for RET-Altered Thyroid Cancers
    U.S. Food and Drug Administration (FDA)

    FDA Approves Pralsetinib for RET-Altered Thyroid Cancers

    On December 1, 2020, the U.S. Food and Drug Administration (FDA) approved pralsetinib for patients aged 12 years and older with advanced or metastatic RET-mutant medullary thyroid cancer who require systemic therapy or RET fusion-positive therapy and who are refractory to radioactive iodine (if radioactive iodine is appropriate).

    December 02, 2020
    FDA Offers Guidance to Enhance Diversity in Clinical Trials
    Cultural/ethnic issues

    FDA Offers Guidance to Enhance Diversity in Clinical Trials

    The COVID-19 coronavirus continues to smother the United States, and nationwide efforts to flatten the curve aren’t lowering cases or preventing deaths. U.S. Food and Drug Administration (FDA) Commissioner Stephen M. Hahn, MD, an oncologist by training and profession, addressed the actions needed to combat COVID-19. One in particular is ensuring that clinical trials accurately reflect diverse populations.

    December 02, 2020
    FDA Grants Accelerated Approval to Naxitamab for High-Risk Neuroblastoma in Bone or Bone Marrow
    Clinical practice

    FDA Grants Accelerated Approval to Naxitamab for High-Risk Neuroblastoma in Bone or Bone Marrow

    On November 25, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to naxitamab (Danyelza®) in combination with granulocyte-macrophage colony-stimulating factor for pediatric patients one year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who demonstrate a partial response, minor response, or stable disease to prior therapy.

    November 30, 2020
    COVID-19 Drug Reference Sheet: Bamlanivimab
    COVID-19

    COVID-19 Drug Reference Sheet: Bamlanivimab

    On November 9, 2020, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization for bamlanivimab, an unapproved agent, to treat mild to moderate cases of the COVID-19 coronavirus. EUAs are not FDA approvals; rather, they authorize use of an unapproved medication in an emergency setting. Bamlanivimab’s initial supply is limited, but the manufacturer announced increased production and distribution in early 2021.

    November 20, 2020
    FDA Grants Accelerated Approval to Pembrolizumab for Locally Recurrent Unresectable or Metastatic TNBC
    U.S. Food and Drug Administration (FDA)

    FDA Grants Accelerated Approval to Pembrolizumab for Locally Recurrent Unresectable or Metastatic TNBC

    On November 13, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with chemotherapy for the treatment of patients with locally recurrent unresectable or metastatic triple negative breast cancer (TNBC) whose tumors express PD-L1 (combined positive score [CPS] ≥ 10) as determined by an FDA-approved test. FDA also approved the PD-L1 IHC 22C3 pharmDx as a companion diagnostic for selecting patients with TNBC for pembrolizumab.

    November 16, 2020
    Lohxa, LLC, Recalls Chlorhexidine Gluconate Oral Rinse Because of Microbial Contamination
    U.S. Food and Drug Administration (FDA)

    Lohxa, LLC, Recalls Chlorhexidine Gluconate Oral Rinse Because of Microbial Contamination

    Lohxa, LLC, issued a voluntary recall of five lots of its alcohol-free chlorhexidine gluconate oral rinse USP 0.12% because of a risk that the product may be contaminated with the bacteria Burkholderia lata. The U.S Food and Drug Administration announced the recall on November 9, 2020. 

    November 10, 2020
    Oncology Drug Reference Sheet: Lurbinectedin
    Clinical practice

    Oncology Drug Reference Sheet: Lurbinectedin

    In June 2020, the U.S. Food and Drug Administration granted accelerated approval to lurbinectedin (ZepzelcaTM) for adults with metastatic small cell lung cancer (SCLC) whose disease has progressed on or after platinum-based chemotherapy. The approval adds a second choice for patients who experience treatment-resistant SCLC progression, who previously had only topotecan as an option.

    October 20, 2020
    FDA Approves Nivolumab and Ipilimumab for Malignant Pleural Mesothelioma
    U.S. Food and Drug Administration (FDA)

    FDA Approves Nivolumab and Ipilimumab for Malignant Pleural Mesothelioma

    On October 2, 2020, the U.S. Food and Drug Administration (FDA) approved nivolumab in combination with ipilimumab for the first-line treatment of adults with malignant pleural mesothelioma that cannot be removed by surgery. This is the first drug regimen approved for mesothelioma in 16 years and the second FDA-approved systemic therapy for mesothelioma. 

    October 05, 2020
    Oncology Drug Reference Sheet: Zanubrutinib
    Clinical practice

    Oncology Drug Reference Sheet: Zanubrutinib

    Zanubrutinib (BrukinsaTM) received U.S. Food and Drug Administration accelerated approval on November 14, 2019, for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy.

    September 22, 2020
    FDA Approves Pralsetinib for Lung Cancer With RET Gene Fusions
    U.S. Food and Drug Administration (FDA)

    FDA Approves Pralsetinib for Lung Cancer With RET Gene Fusions

    On September 4, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to pralsetinib (Gavreto™) for adult patients with metastatic, RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test.

    September 10, 2020
    FDA Rejects Atezolizumab in Combination With Paclitaxel as Treatment for Breast Cancer 
    U.S. Food and Drug Administration (FDA)

    FDA Rejects Atezolizumab in Combination With Paclitaxel as Treatment for Breast Cancer 

    On September 8, 2020, the U.S. Food and Drug Administration (FDA) announced it did not approve atezolizumab (Tecentriq®) in combination with paclitaxel for treatment of breast cancer after a clinical trial studying the use of atezolizumab and paclitaxel in patients with previously untreated inoperable locally advanced or metastatic triple negative breast cancer (mTNBC) showed the drug combination did not work to treat the disease.   

    September 09, 2020
    FDA Designates Majority of BD’s June 30 Alaris Pump Recall as Class I
    U.S. Food and Drug Administration (FDA)

    FDA Designates Majority of BD’s June 30 Alaris Pump Recall as Class I

    On September 1, 2020, the U.S. Food and Drug Administration (FDA) designated three of the situations involved in BD’s June 30, 2020, previously announced voluntary recall of several models of its Alaris™ system as class I recalls. Class I recall designation indicates a reasonable probability that the use of the product will cause serious adverse health consequences or death.

    September 02, 2020
    FDA Approves Azacitidine Tablets for Acute Myeloid Leukemia
    U.S. Food and Drug Administration (FDA)

    FDA Approves Azacitidine Tablets for Acute Myeloid Leukemia

    On September 1, 2020, the U.S. Food and Drug Administration (FDA) approved azacitidine tablets for continued treatment of patients with acute myeloid leukemia who achieved first complete remission (CR) or CR with incomplete blood count recovery following intensive induction chemotherapy and who are unable to complete intensive curative therapy.

    September 02, 2020
    FDA Study Reveals Higher COVID-19 Death Rate For Patients With Cancer
    Patient advocacy

    FDA Study Reveals Higher COVID-19 Death Rate for Patients With Cancer

    The U.S. Food and Drug Administration’s (FDA’s) Oncology Center of Excellence confirmed that those with immunocompromised systems, including cancer, are at greater risk for serious outcomes or death after contracting the COVID-19 coronavirus.

    August 12, 2020
    FDA Approves First Liquid Biopsy NGS Companion Diagnostic Test for NSCLC
    U.S. Food and Drug Administration (FDA)

    FDA Approves First Liquid Biopsy NGS Companion Diagnostic Test for NSCLC

    On August 7, 2020, the U.S. Food and Drug Administration (FDA) approved the Guardant360 CDx assay as the first liquid biopsy companion diagnostic that also uses next-generation sequencing (NGS) technology to identify patients with specific types of mutations of the epidermal growth factor receptor gene in patients with metastatic non-small cell lung cancer (NSCLC). This is the first approval to combine two technologies in one diagnostic test to guide treatment decisions. 

    August 11, 2020
    FDA Announces Program on PROs From Cancer Clinical Trials
    U.S. Food and Drug Administration (FDA)

    FDA Program Shares PROs From Cancer Clinical Trials

    Cancer clinical trials often collect patient-reported outcome (PRO) data, but the information is generally used just for that trial. Recognizing the value of making it available to healthcare providers everywhere, in July 2020, the U.S. Food and Drug Administration (FDA) launched Project Patient Voice, a pilot program designed to share clinical trial PROs on an easy-to-access website.

    August 11, 2020
    FDA Grants Accelerated Approval to Belantamab Mafodotin-Blmf for Multiple Myeloma
    U.S. Food and Drug Administration (FDA)

    FDA Grants Accelerated Approval to Belantamab Mafodotin-Blmf for Multiple Myeloma

    On August 5, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to belantamab mafodotin-blmf (Blenrep) for adult patients with relapsed or refractory multiple myeloma who received at least four prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.

    August 06, 2020
    FDA Grants Accelerated Approval to Tafasitamab-Cxix for Diffuse Large B-Cell Lymphoma
    U.S. Food and Drug Administration (FDA)

    FDA Grants Accelerated Approval to Tafasitamab-Cxix for Diffuse Large B-Cell Lymphoma

    On July 31, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to tafasitamab-cxix (Monjuvi®), a CD19-directed cytolytic antibody, indicated in combination with lenalidomide for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low-grade lymphoma, and who are not eligible for autologous stem cell transplant.

    August 04, 2020
    FDA Approves Atezolizumab for BRAF V600 Unresectable or Metastatic Melanoma
    U.S. Food and Drug Administration (FDA)

    FDA Approves Atezolizumab for BRAF V600 Unresectable or Metastatic Melanoma

    On July 30, 2020, the U.S. Food and Drug Administration (FDA) approved atezolizumab (Tecentriq®) in combination with cobimetinib and vemurafenib for patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.

    August 03, 2020
    Oncology Drug Reference Sheet: Enfortumab Vedotin-Ejfv
    U.S. Food and Drug Administration (FDA)

    Oncology Drug Reference Sheet: Enfortumab Vedotin-Ejfv

    Enfortumab vedotin-ejfv (Padcev™) was granted accelerated approval in December 2019 for adults with locally advanced or metastatic urothelial cancer who previously received an immune checkpoint inhibitor (PD-1 or PD-L1 inhibitor) and platinum-containing therapy.

    July 28, 2020
    FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory MCL
    U.S. Food and Drug Administration (FDA)

    FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory MCL

    On July 24, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to brexucabtagene autoleucel (Tecartus™), a CD19-directed genetically modified autologous T cell immunotherapy, for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.

    July 27, 2020
    FDA Approves Oral Combination of Decitabine and Cedazuridine for Myelodysplastic Syndromes
    U.S. Food and Drug Administration (FDA)

    FDA Approves Oral Combination of Decitabine and Cedazuridine for Myelodysplastic Syndromes

    On July 7, 2020, the U.S. Food and Drug Administration (FDA) approved an oral combination of decitabine and cedazuridine (Inqovi®) for adult patients with myelodysplastic syndromes, including the following:

    July 08, 2020
    FDA Launches Pilot Program on Patient-Reported Outcomes
    Patient reported outcomes (PROs)

    FDA Launches Pilot Program on Patient-Reported Outcomes

    Facilitating the provision of patient-centered care is an ONS priority. But until recently, quality information from the patient’s perspective was limited. This kind of information is often unavailable, limited in its breadth, or solicited from patients too late in the healthcare process, making their experience less understandable than necessary. In response, the U.S. Food and Drug Administration’s (FDA’s) Oncology Center of Excellence created a pilot program, called Project Patient Voice, that will make patient-reported symptoms from cancer trials available to the public.

    July 08, 2020
    FDA Approves Avelumab for Urothelial Carcinoma Maintenance Treatment
    Oncology drug research

    FDA Approves Avelumab for Urothelial Carcinoma Maintenance Treatment

    On June 30, 2020, the U.S. Food and Drug Administration (FDA) approved avelumab (Bavencio®) for maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) that has not progressed with first-line platinum-containing chemotherapy.

    July 02, 2020
    FDA Approves Pembrolizumab for First-Line Treatment of MSI-H/dMMR Colorectal Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Pembrolizumab for First-Line Treatment of MSI-H/dMMR Colorectal Cancer

    On June 29, 2020, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda®) for first-line treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.

    June 30, 2020
    FDA Approves Combination of Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf for HER2-Positive Breast Cancer
    Oncology drug research

    FDA Approves Combination of Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf for HER2-Positive Breast Cancer

    On June 29, 2020, the U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf (Phesgo™) via subcutaneous injection for use in combination with docetaxel to treat patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.

    June 30, 2020
    FDA Approves Pembrolizumab for Treatment of Cutaneous Squamous Cell Carcinoma
    Oncology drug research

    FDA Approves Pembrolizumab for Treatment of Cutaneous Squamous Cell Carcinoma

    On June 24, 2020, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda®) for patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) that is not curable with surgery or radiation.

    June 25, 2020
    FDA Approves Selinexor for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Oncology drug research

    FDA Approves Selinexor for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    On June 22, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to selinexor (Xpovio®) for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy.

    June 23, 2020
    HIV-Positive Patients With Cancer Need to Be Included in Clinical Drug Trials
    U.S. Food and Drug Administration (FDA)

    HIV-Positive Patients With Cancer Need to Be Included in Clinical Drug Trials

    Viral infections such as HIV may increase a person’s risk for developing several malignancies. However, most investigational drug studies exclude HIV-positive patients with cancer and optimal treatment regimens remain unknown.

    June 23, 2020
    FDA Grants Accelerated Approval to Tazemetostat for Follicular Lymphoma
    U.S. Food and Drug Administration (FDA)

    FDA Grants Accelerated Approval to Tazemetostat for Follicular Lymphoma

    On June 18, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat (Tazverik™), an EZH2 inhibitor, for adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation, as detected by an FDA-approved test, who have received at least two prior systemic therapies and have no satisfactory alternative treatment options.

    June 19, 2020
    FDA Approves Pembrolizumab for Patients With TMB-H Solid Tumors
    U.S. Food and Drug Administration (FDA)

    FDA Approves Pembrolizumab for Patients With TMB-H Solid Tumors

    On June 16, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab (Keytruda®) for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥ 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and have no satisfactory alternative treatment options.

    June 17, 2020
    FDA Extends Indication for Gemtuzumab Ozogamicin for CD33-Positive AML in Pediatric Patients
    U.S. Food and Drug Administration (FDA)

    FDA Extends Indication for Gemtuzumab Ozogamicin for CD33-Positive AML in Pediatric Patients

    On June 16, 2020, the U.S. Food and Drug Administration (FDA) extended the indication of gemtuzumab ozogamicin (Mylotarg™) for newly-diagnosed CD33-positive acute myeloid leukemia (AML) to include pediatric patients aged 1 month and older.

    June 16, 2020
    FDA Grants Accelerated Approval to Lurbinectedin for Metastatic Small Cell Lung Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Grants Accelerated Approval to Lurbinectedin for Metastatic Small Cell Lung Cancer

    On June 15, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to lurbinectedin (Zepzelca™) for adult patients with metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy.

    June 16, 2020
    FDA Approves Nivolumab for Esophageal Squamous Cell Carcinoma
    U.S. Food and Drug Administration (FDA)

    FDA Approves Nivolumab for Esophageal Squamous Cell Carcinoma

    On June 10, 2020, the U.S. Food and Drug Administration (FDA) approved nivolumab (Opdivo®) for patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.

    June 11, 2020
    FDA Approves Ramucirumab Plus Erlotinib for First-Line Treatment of Metastatic NSCLC
    Oncology drug research

    FDA Approves Ramucirumab Plus Erlotinib for First-Line Treatment of Metastatic NSCLC

    On May 29, 2020, the U.S. Food and Drug Administration (FDA) approved ramucirumab (Cyramza®) in combination with erlotinib for first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 mutations. 

    June 01, 2020
    FDA Approves Nivolumab Plus Ipilimumab and Chemotherapy for First-Line Treatment of Metastatic NSCLC
    Oncology drug research

    FDA Approves Nivolumab Plus Ipilimumab and Chemotherapy for First-Line Treatment of Metastatic NSCLC

    On May 26, 2020, the U.S. Food and Drug Administration (FDA) approved the combination of nivolumab plus ipilimumab  and two cycles of platinum-doublet chemotherapy as first-line treatment for patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no epidermal growth factor receptor or anaplastic lymphoma kinase genomic tumor aberrations.

    May 27, 2020
    FDA Approves Brigatinib for ALK-Positive, Metastatic NSCLC
    U.S. Food and Drug Administration (FDA)

    FDA Approves Brigatinib for ALK-Positive, Metastatic NSCLC

    On May 22, 2020, the U.S. Food and Drug Administration (FDA) approved brigatinib (Alunbrig®) for adult patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC). FDA also approved the Vysis ALK Break Apart FISH Probe Kit as a companion diagnostic for brigatinib. 

    May 26, 2020
    FDA Approves Olaparib for HRR Gene-Mutated, Metastatic, Castration-Resistant Prostate Cancer
    Oncology drug research

    FDA Approves Olaparib for HRR Gene-Mutated, Metastatic, Castration-Resistant Prostate Cancer

    On May 19, 2020, the U.S. Food and Drug Administration (FDA) approved olaparib (Lynparza®) for adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated, metastatic, castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.

    May 20, 2020
    FDA Approves Atezolizumab for First-Line Treatment of Metastatic NSCLC With High PD-L1 Expression
    U.S. Food and Drug Administration (FDA)

    FDA Approves Atezolizumab for First-Line Treatment of Metastatic NSCLC With High PD-L1 Expression

    On May 18, 2020, the U.S. Food and Drug Administration (FDA) approved atezolizumab (Tecentriq®) for first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (PD-L1 staining ≥ 50% of tumor cells [TC] or PD-L1-stained tumor-infiltrating immune cells [IC] covering ≥ 10% of the tumor area), with no epidermal growth factor receptor or anaplastic lymphoma kinase genomic tumor aberrations. 

    May 19, 2020
    • Current page 1
    • Page 2
    • Page 3
    • Page 4
    • Page 5
    • Page 6
    • Page 7
    • Page 8
    • Next page
    • Last page Last »
    Trending Topics
    • Treatments
    • Research
    • Safety
    • COVID-19
    • ONS Congress
    • Clinical practice
    • U.S. Food and Drug Administration (FDA)
    • Health Policy
    • Immunotherapy
    • Oncology nurse influence
    View All Topics
    Home
    News, Views, and Advocacy From the Oncology Nursing Society
  • Legal Notices
  • Contact Us
  • Conferences
  • Advertising
  • Newsroom
  • Sitemap
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • ONS
  • Oncology Nursing Foundation
  • ONCC
  • © Copyright 2021 Oncology Nursing Society
     
    Back to Top ▲